What have we learned about renal denervation? Medtronic's SYMPLICITY HTN-3 trial and global SYMPLICITY registry - Data from the clinical setting and real-world experience

With an unrestricted educational grant from MEDTRONIC

Chairpersons: M. Böhm, R. Schmieder
Panellists: F. Mahfoud, M. Patel

Summary

Consult this session on Medtronic's SYMPLICITY HTN-3 trial and global SYMPLICITY registry, if you want to learn more about renal denervation.

This video is offered by Medtronic.

Learning Objectives

  • To learn insights and new data from the SYMPLICITY HTN-3 clinical trial
  • To discuss what we have learned from SYMPLICITY HTN-3 and to evaluate the real-world body of evidence we now have for renal denervation
  • To discuss what the future holds for renal denervation and what data we might see in the future

Presentations available when logged in:

  • Introduction and objectives
  • What we have learned from SYMPLICITY HTN-3
  • SYMPLICITY HTN-3 subset analysis
  • Global SYMPLICITY registry subset analysis
  • Pooled safety analysis
  • Take-home message - What the future holds for renal denervation